United Therapeutics Corporation
$578.37
▲
0.86%
2026-04-22 10:12:13
www.unither.com
NMS: UTHR
Explore United Therapeutics Corporation stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$25.34 B
Current Price
$578.37
52W High / Low
$607.89 / $272.12
Stock P/E
20.76
Book Value
$162.6
Dividend Yield
—
ROCE
20.73%
ROE
19.71%
Face Value
—
EPS
$27.86
Exp Qtr EPS
—
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
1,400
Beta
0.75
Debt / Equity
0.53
Current Ratio
6.61
Quick Ratio
6.28
Forward P/E
16.79
Price / Sales
7.87
Enterprise Value
$22.17 B
EV / EBITDA
13.85
EV / Revenue
6.97
Rating
Buy
Target Price
$635.42
EPS Forecast (FY)
—
Pros
- Healthy return on equity.
- Efficient use of capital employed.
- Short-term liquidity looks comfortable.
- Strong operating margin profile.
- Net margin remains healthy.
Cons
- Some data points may be missing or delayed because the source is not an official exchange feed.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Shuttle Pharmaceuticals Holdings, Inc. | $0.99 | — | $5.7 M | — | -791.36% | -7.91% | $11.25 / $0.5 | $1.13 |
| 2. | Liquidia Corporation | $37.66 | — | $3.32 B | — | -26.74% | -1.11% | $46.67 / $11.85 | $0.51 |
| 3. | Lantheus Holdings, Inc. | $83.97 | 23.41 | $5.47 B | — | 16.66% | 21.45% | $108.91 / $47.25 | $16.87 |
| 4. | Hims & Hers Health, Inc. | $28.91 | 56.32 | $6.55 B | — | 6.03% | 25.23% | $70.43 / $13.74 | $2.38 |
| 5. | Gelteq Limited | $0.7 | — | $7.5 M | — | -31.25% | -42.99% | $4.11 / $0.64 | $1.09 |
| 6. | Organigram Global Inc. | $1.51 | 15.08 | $274.04 M | — | -3.51% | 4.64% | $3.09 / $1.37 | $1.97 |
| 7. | Emergent BioSolutions Inc. | $8.35 | 8.47 | $445.43 M | — | 9.47% | 10.46% | $14.06 / $4.45 | $10.03 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 790.2 M | 799.5 M | 798.6 M | 794.4 M | 735.9 M | — |
| Operating Profit | 357.5 M | 389.3 M | 386.2 M | 382.8 M | 363.7 M | — |
| Net Profit | 364.3 M | 338.7 M | 309.5 M | 322.2 M | 301.3 M | — |
| EPS in Rs | 8.31 | 7.73 | 7.06 | 7.35 | 6.87 | — |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 3.18 B | 2.88 B | 2.33 B | 1.94 B |
| Operating Profit | 1.52 B | 1.45 B | 1.18 B | 979.7 M |
| Net Profit | 1.33 B | 1.2 B | 984.8 M | 727.3 M |
| EPS in Rs | 30.45 | 27.27 | 22.47 | 16.59 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 7.88 B | 7.36 B | 7.17 B | 6.04 B |
| Total Liabilities | 783.8 M | 920 M | 1.18 B | 1.25 B |
| Equity | 7.1 B | 6.44 B | 5.98 B | 4.8 B |
| Current Assets | 3.7 B | 3.87 B | 3.55 B | 3.38 B |
| Current Liabilities | 560.6 M | 738.1 M | 804.4 M | 343.2 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | 1.56 B | 1.33 B | 978 M | 802.5 M |
| Investing CF | -551.3 M | 417.2 M | -719.6 M | -811.5 M |
| Financing CF | -1.15 B | -1.25 B | -11.9 M | 75.4 M |
| Free CF | 1.04 B | 1.08 B | 747.6 M | 663.7 M |
| Capex | -526 M | -246.5 M | -230.4 M | -138.8 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | 23.63% | 20.2% | — | — |
| Earnings Growth % | 21.35% | 35.4% | — | — |
| Profit Margin % | 41.53% | 42.31% | 37.56% | — |
| Operating Margin % | 50.33% | 50.91% | 50.6% | — |
| Gross Margin % | 89.24% | 88.94% | 92.17% | — |
| EBITDA Margin % | 57.5% | 59.58% | 53.42% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.